Skip to content

Nuvectis Pharma, Inc. NVCT Change in Accrued Liabilities

Change in Accrued Liabilities at other companies

Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
$432.21K+67.1%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
-$1.56M+28.9%
Nuvation Bio logo
Nuvation BioNUVB
-$12.32M-37.8%
Nuvalent, Inc. logo
Nuvalent, Inc.NUVL
-$2.13M-472%
Exelixis logo
ExelixisEXEL
$4.04M-12.2%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$2.33M+91.4%

Other financials

Income statement

See full
Operating income-$6.3M-12.4%
Net income-$6.1M-13.5%
EPS (diluted)-$0.26+3.7%

Balance sheet

See full
Cash & equivalents$25.1M-15.9%
Total equity$14.2M-32.1%
Total assets$25.4M-15.8%

Cash flow

See full
Operating cash flow-$6.5M-56.0%

Valuation

See full
Market cap$739.27M+335%

Returns & leverage

See full
Return on equity-154.4%+79.4pp
Current ratio2.3×-1.0×

Where this comes from

Reported directly by Nuvectis Pharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.

The official record: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvectis Pharma, Inc.'s change in accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvectis Pharma, Inc.'s change in accrued liabilities?
Nuvectis Pharma, Inc. (NVCT) reported change in accrued liabilities of -$79K in Q1 2026.
How has Nuvectis Pharma, Inc.'s change in accrued liabilities changed year-over-year?
Nuvectis Pharma, Inc.'s change in accrued liabilities decreased by 416.0% year-over-year, from $25K to -$79K.
What does change in accrued liabilities mean?
Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.